Christina Bennett, MS

Christina Bennett, MS, is an independent medical journalist who writes about a variety of medical topics, including oncology, health care policy, and cell and gene therapies. She has a bachelor's degree in biomedical science and a master’s degree in science and technology journalism, both from Texas A&M University. She is a member of the Association of Healthcare Journalists and the National Association of Science Writers and was one of a dozen journalists selected for the 2017 National Cancer Reporting Fellowships.

All articles by Christina Bennett, MS

According to experts, PARP inhibition, radiopharmaceuticals, and immunotherapy could revolutionize h

Prostate Cancer

Comparison of Multimodal Approaches in High-Risk Prostate Cancer

Christina Bennett, MS

October 5, 2018

Men treated with radical prostatectomy plus radiotherapy for locally or regionally advanced prostate cancer had improved survival but worse adverse events.

Watson, hoped to be a major source for clinicians, is limited by an inability to interpret clinical

Renal Cell Carcinoma

Robotic Tumor Enucleation Appears Safe for Sporadic Renal Cell Carcinoma

Christina Bennett, MS

October 3, 2018

Long-term oncologic outcomes of patients with sporadic RCC who underwent robotic tumor enucleation suggest the procedure is safe.

Nearly half of patients with CML who achieved a deep molecular response following treatment with nil

Sarcoma

Trial Underway for Checkpoint Blockade in Soft Tissue Sarcoma

Christina Bennett, MS

October 3, 2018

An open-label, single-center, phase 2 trial is underway to evaluate neoadjuvant nivolumab alone and in combination with ipilimumab in soft tissue sarcoma.

Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journa

General Oncology

Fall of Star Cancer Researcher Brings Broader Picture Into View

Christina Bennett, MS

October 2, 2018

Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.

Sarcoma

Acceptable Safety for Trabectedin Plus Olaparib in Unresectable Sarcoma

Christina Bennett, MS

October 2, 2018

Trabectedin plus olaparib showed acceptable safety and tolerability in patients with metastatic and unresectable bone and soft-tissue sarcomas.

Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do n

Bladder Cancer

Bladder Cancer Surveillance Not Aligned With Risk: Study of VA Facilities

Christina Bennett, MS

October 1, 2018

Patients at VA facilities with high-risk early-stage bladder cancer tend to have cystoscopic surveillance at frequencies similar to those with low-risk disease.

Still unresolved is whether to screen the general population for MGUS, a largely asymptomatic condit

Multiple Myeloma

Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed

Christina Bennett, MS

September 24, 2018

First-degree relatives of patients with multiple myeloma were found to be at a higher risk of developing monoclonal gammopathy of undetermined significance.

If a patient develops any adverse event while on ponatinib, clinicians should perform a risk-benefit

Lymphoma

Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma

Christina Bennett, MS

September 24, 2018

Sequential dosing of brentuximab vedotin before and after standard doxorubicin, vinblastine, and dacarbazine showed a survival benefit in a phase II trial.

Traditional genetic testing historically included the sequential analysis of single and generally we

Prostate Cancer

Prostate Cancer Drug Resistance Mediated by Epigenetic Changes

Christina Bennett, MS

September 24, 2018

Epigenetic changes in the tumor microenvironment may explain why prostate cancer patients develop resistance to androgen signaling deprivation therapy.